VJHemOnc is committed to improving our service to you

ASH 2019 | Magrolimab plus aza: phase 1b data in MDS/AML

VJHemOnc is committed to improving our service to you

David Sallman

Magrolimab is a first-in-class antibody targeting CD47, a macrophage immune checkpoint and “don’t eat me” signal on malignant cells. Blocking CD47 with magrolimab may enable the body’s immune system to find and eliminate these cells. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the ongoing phase 1 trial (NCT03248479) of magrolimab in combination with azacitidine in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter